

## References

- ALAOUI-YOUSSEFI, A., LAMPROGLOU, I., DRIEU, K., EMERIT, I., 1999. Antclastogenic effects of Ginkgo biloba extract (Egb761) and some of its constituents in irradiated rats. *Mutation Research – Genetic Toxicology and Environmental Mutagenesis*. 443, 99-104.
- ALMEIDA, J.C., GRIMSLEY, E.W., 1996. Coma from the health food store: Interaction between kava and alprazolam. *Annals of Internal Medicine*, 125, 940-941.
- ANONYMOUS., 1999. Raw materials III: Nutrition Industry Value Chain. *Nutritional Business Journal*, 4(10/11), 1-13.
- ANTON,R., 1997. Hypericum perforatum : Quality control, Analytical and Therapeutic Monograph. In R.UPTON, ed. *American Herbal Pharmacopoeia and Therapeutic Compendium*. Santa Cruz, CA: Am Herbal press, 4-32
- AUSTIN, J.A.,1998. Why patients use alternative medicine: results of a national study. *Journal of the American Medical Assosiation*, 279,1543-1548.
- BALICK, M.J. 1994. Ethnobotany, Drug development and Biodiversity Conservation – Exploring the linkages. In: G.T. PRANCE, ed. *Ethnobotany and the search for new drugs*. Wiley, Chichester (Ciba Foundation Symposium 185) p4-24
- BASS, K., 2001. INA's Methods Validation Program [online]. Available from <http://www.neutraceuticalinstitute.com> [10 February 2001]
- BLUMENTHAL, M., BUSSE, W.R., GOLDBERG, A., et al, eds., 1998. *The Complete German Commision E Monographs: Therapeutic Guide to Herbal Medicines*. Austin: American Botanical Council.
- BRADLEY, P., 1996. *The British Herbal Pharmacopoeia*. 4<sup>th</sup> ed. Exeter: British Herbal Medicine Association.
- BROCKMOLLER ,J., REUM, T., BAUER, S., KERB, R., HUBNER, W.D., ROOTS, I., 1997. Hypericin and Pseudohypericin: Pharmacokinetics and effects on photosensitivity in humans. *Pharmacopsychiatry*, ;30(2), 94-101.

BROWN, D.J., 1998. *Ginkgo Biloba*. Continuing education module. New hope institute of retailing, 3-6.

BROWN, N.D, GABY, A.R, RIECHERT, R. 1999. Natural remedies for depression, *Nutrition science news*, 2,6.

BUSSE, W., 1994. History and chemistry of Ginkgo biloba. *Revista Brasileira de Neur*, 30(1), 3S-6S.

CAMERON, H., 1998. Guidelines for stability testing of Herbal Products. *Department of Health and Family Services*, Australia.

COHEN, R., et al. 1997. Disorders due to physical agents. *In: L.M.Tierney, S.J. McPhee, M.A. Papadakis, eds. Current Medical Diagnosis and Treatment*. 36<sup>th</sup> ed.London: Prentice-Hall International. 1435.

COTT, J.M., 1997. In vitro receptor binding and enzyme inhibition by *Hypericum perforatum* extract. *Pharmacopsychiatry*, 30(2), 108-12.

DAVIES, L.P., DREW, C.A., DUFFIELD, P., HOHNSTON, G.A.R., JAMIESON, D.D., 1992. Kava pyrones and resin: Studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. *Pharmacology and Toxicology*, 71,120-126.

DEFEUDIS, F.V., 1998. Ginkgo biloba extract (Egb 761):from chemistry to clinic. Wiesbaden, Germany:Ullstein Medical

DRIEU, K., 1988. Preparation and definition of Ginkgo biloba extract. *In: E.W. FUNFGELD ed. Ginkgo Biloba: Recent results in Pharmacology and Clinic*. Berlin:Springer-Verlag, 32-36.

EISENBERG, D., KESSLER, R.C., FOSTER, C., et al. 1993. Unconventional medicine in the United states: Prevalence, costs and patterns of use. *New England Journal of Medicine*, 328, 246-252.

ERNST, E., 1996. Ginkgo biloba extract in peripheral arterial diseases:a systematic research based on controlled studies in the literature. *Fortschritte Medizin*, 114, 85-87.

FUGH-BERMAN, A., COTT, J.M., 1999. Dietary supplements and natural products as psychotherapeutic agents. *Psychosomatic medicine* ,61(5), 712-19.

GIBALDI, M.,1991. *Biopharmaceutics and clinical pharmacokinetics*. 4<sup>th</sup> ed. Philadelphia, Lea & Febiger.

GLEITZ, J., FRIESE,J., BEILE, A., AMERI, A., PETERS, T., 1996. Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na<sup>+</sup>channel receptor sites. *European Journal of Pharmacology*, 315(1), 89-97.

GORDON, J.B., 1998. SSRI's and St John's wort: Possible toxicity ?. *American Family Physician*, 57, 950-953.

HAHN,G., 1992. *Hypericum perforatum* (St John's wort) -a medicinal herb used in antiquity and still of interest today. *Journal of Naturopathic Medicine*. 3, 94-96.

HADLEY, S.K., PETRY, J.J.,1999. Medicinal Herbs: A Primer for Primary care.*Hospital practice*, 34,105-106.

HALLORAN,K., LEHMANN, R., PENMAN, K. 2000. Stability profiling of Echinacea Products in terms of caffeic acid derivates and alkamides. *MediHerb :Herbal Medicine Excellence*.

HEILIGENSTEIN, E., GUENTHER,G., 1998. Over-the-counter Psychotropics: A Review of Melatonin, St John' wort, Valerian, and Kava Kava. *Journal of American college health*, 6,271-276.

HERBERG, K.W., 1993. Effect of kava special extract WS1490 combined with ethyl alcohol on safety-relevant performance parameters. *Blutalkohol* ,30, 96-105.

HER MAJESTY'S STATIONARY OFFICE, 1998. *The British Pharmacopoeia*. Norwich, United Kingdom: The Stationary office, NR3 1BQ

HINDEMARCH, I., SUBHAN, Z., 1984. The pharmacological effects of Ginkgo biloba extract in normal healthy volunteers. *International Journal of Clinical Pharmacology*, 4, 89-93.

HOBBS, C., 1989. St John's wort: *Hypericum perforatum* L. A review. *HerbalGram*, 18/19, 24-33.

HOFFERBERTH, B., 1994. The efficacy of Egb761 in patients with senile dementia of the Alzheimer type: a double blind placebo-controlled study on different levels of investigation. *Human Psychopharmacology*, 9, 215-222.

HOLZL, J., DEMISCH, L., GOLLNIK, B., 1989. Investigations about antidepressive and mood changing effects of *Hypericum perforatum*. *Planta Medica*, 55, 643.

JOHNSTON, B.A., 1997. One third of Nation's adults use herbal remedies: Market estimated at \$3.24 billion. *Herbalgram*, 40, 49.

KANOWSKI, S., HERRMANN, W.M., STEPHAN, K., WIERICH, W., HOERR, R., 1996. Proof of efficacy of the Ginkgo biloba special extract Egb761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. *Pharmacopsychiatry*, 29, 47-56.

KLEIJNEN, J., KNIPSCHILD, P., 1992. Ginkgo biloba. *Lancet*, 340, 1136-1139

KRIEGLSTEIN, J., 1994. Neuroprotective properties of Ginkgo biloba constituents. *Zeitschrift für Phytotherapie*, 15, 92-96.

LAVIE, G., MAZUR, Y., LAVIE, D., MURUELO, D., 1995. The chemical and biological properties of hypericin, - a compound with a broad spectrum of biological activities. *Medicinal research reviews*. 15, 111-119.

LEHMANN, E., KINZLER, E., FRIEDEMANN, J., 1996. Efficacy of a special kava extract (*Piper methysticum*), in patients with states of anxiety, tension and excitedness of nonmental origin – a double blind placebo controlled study of four weeks treatment. *Phytomedicine*, 2, 113-119.

LIBERTI, L.E., DERMADEROSIAN, A., 1978. Evaluation of commercial ginseng products. *Journal of Pharmaceutical Science*, 67, 1487-1489.

LINDENBERG, D., PITULE-SCHODEL, H.D., 1990. L-Kavain in comparison with oxazepam in anxiety disorders:a double blind study of clinical effectiveness. *Fortschritte Medizin*, 108, 49-54.

LINDLE, K., RAMIREZ, G., MULROW, C.D., PAULS, A., WEIDENHAMMER, W., MELCHART, D.,1996. St John's wort for depression-an overview and meta-analysis of randomized clinical trials. *British Medical Journal*, 313, 253-8.

LUND, W., 1994. *The Pharmaceutical Codex: Principles and practice of Pharmaceutics*. 12<sup>th</sup> edition. London: The Pharmaceutical Press.

MAITRA, I., MARCOCCI, L., DROY-LEFAIS, M., PACKER, L., 1995. Peroxyl radical scavenging activity of Ginkgo extract Egb761. *Biochemical Pharmacology*, 49, 1649-1655.

MORRISON, J., 1935, *The Journal of James Morisson*, London: Golden Cockerel press, 151.

MULLER,W.E., ROLLI, M., SCHAFER, C., HAFNER, U., 1997. Effects of Hypericum extract (LI160) in biochemical models of antidepressant activity. *Pharmacopsychiatry*, 30(1), 102-107.

MULLER, W.E., ROSSOL, R., 1994. Effects of Hypericum extract on the expression of serotonin receptors. *Journal of Geriatric Psychiatry and Neurology*, 7(1), S63-S64.

MURRAY, M.T., 1995. *The Healing power of herbs*. 2<sup>nd</sup>, Rocklin, CA: Prima publishing, 210-219.

NORTON, S.A., RUZE, P., 1994. Kava dermatophy. *Journal of the American Academy of Dermatology*, 31, 89-97.

O'HARA, M., KIEFER, D., FARREL, K., KEMPER, K., 1998. A review of 12 Commonly Used Medicinal Herbs. *Archives of Family Medicine*, 7(6), 523-536.

OOSTENTIN, M.LACOUR , eds. *Effects of Ginkgo biloba extract (Egb761) on the Central Nervous System*. Paris: Elsevier,95-104.

ORTH, H.C.J., RENDEL, C., SCHMIDT, P.C., 1998. Isolation, Purity Analysis and Stability of Hyperforin as a Standard Material from *Hypericum perforatum* L. *Journal of pharmacy and pharmacology*, 51(2), 193-200.

RAI, G.S., SHOVLIN, C., WESNES, K.A., 1991. A double-blind, placebo controlled study of ginkgo biloba extract ("Tanakan") in elderly outpatients with mild to moderate memory impairment. *Current Medical Research and Opinion*, 12, 350-355.

RETIEF, A.C., 2001. *The analysis of sterols and sterolins in Hypoxis hemerocallidea and related herbal medicines*. Thesis (M.Sc). University of Pretoria

ROBBERS, J.E., TYLER, V.E., 1999. *Tyler's Herbs of Choice*. Binghamton: The Haworth herbal press.

RONCIN, J., SCHWARTZ, F., D'ARBIGNY, P., 1996. Egb761 in control of acute mountain sickness and vascular reactivity to cold exposure. *Aviation, Space and Environmental Medicine*, 67, 445-452.

RUBENSTEIN, M.H., 1995. Drug delivery systems: Tablets. In: M.E.AULTON, ed. *Pharmaceutics: The Science of dosage form design*. New York: Churchill Livingstone, 304-321.

RUZE, P., 1990. Kava induced dermatophy: a niacin deficiency ?. *Lancet*, 335, 1442-1445.

SANDERS-BUSH, E. MAYER, S., 1996. 5-Hydroxytryptamine (Serotonin) receptor agonists and antagonists. In: J.G.HARDMAN, L.E.LIMBIRD eds. *Goodman and Gilman's Pharmacological Basis of Therapeutics*. 9<sup>th</sup> edition. USA: The McGraw-Hill Companies, Inc, 280-282.

SCHULZ, V., HANSEL, R., TYLER, V.E. 1998. *Rational phytotherapy: a Physician's guide to herbal medicine*. 3<sup>rd</sup> ed. Berlin: Springer-Verlag.

SELIGMAN, N.D. 1998. Kava Kava (*Piper methysticum*). Continuing education module. New hope institute of retailing, 2-6.

SINGH, Y.N., 1992. Kava: an overview. *Journal of Ethnopharmacology*, 37, 13-45

SKOOG, D.A., WEST, D.M., HOLLER, F.J., 1996. *Fundamentals of Analytical Chemistry*. 7<sup>th</sup> ed. Philadelphia: Saunders College Publishing.

SNYDER, L.R., KIRKLAND, J.J., 1979. *Introduction to modern liquid chromatography*. New York: John Wiley.

STEIN, D.G., HOFFMAN, S.W., 1992. Chronic administration of Ginkgo biloba extract (Egb761) can enhance recovery from traumatic brain injury. In: Y. CHRISTEN, J. OOSTENIN, M. LACOR. eds. *Effects of Ginkgo biloba extract (Egb761) on the Central Nervous system*. Paris: Elsevier, 95-104.

STEINMENTZ, E.F. 1960. *Piper methysticum* (kava). Published by the Author, Amsterdam

STOKLOSA, M.J., ANSEL, H.C. 1991. *Pharmaceutical calculations*. 9<sup>th</sup> edition. London: Lea and Febiger.

TYLER, V.E., ROBBERS, J.E., 1999. *Tyler's herbs of choice: The therapeutic use of Phytomedicinals*. London: The Halworth Herbal Press.

TYLER, V.E., 1994. *Herbs of choice. The therapeutic use of Phytomedicinals*. Binghamton, NY: The Halworth Herbal Press

UEBELHACK, R., FRANKE, L., SCHEWE, H.J., 1998. Inhibition of platelet MOA-B by kava pyrone-enriched extract from *Piper methysticum*. *Pharmacopsychiatry*, 31(5), 187-192.

VANDER, A.J., SHERMAN, J.H., LUCIANO, D.S., 1994. Defence Mechanisms of the Body. In: K.M. PRANCAN and J.W. BRADLEY, eds, *Human Physiology: the mechanisms of body function*, 6<sup>th</sup> ed, New York: McGraw-Hill, Inc.

WAGNER, H., BLADT, S. 1996. *Plant Drug Analysis: A Thin Layer Chromatography Atlas*. 2<sup>nd</sup> ed. New York: Springer-Verlag .

WHEATLEY, D., 1977. LI160, an extract of St John's wort versus amitriptylene in mildly to moderately depressed outpatients- a controlled 6-week clinical trial. *Pharmacopsychiatry*, 30(2), 77-80.

WOERDENBAG,H.J., VAN BECK,T.A., 1997. *Ginkgo biloba*. *Adverse Effects of Herbal drugs*.Vol 3. Berlin,Germany: Springer-Verlag.